ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Inspire Investing LLC

Inspire Investing LLC cut its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 63.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,491 shares of the biotechnology company's stock after selling 41,176 shares during the quarter. Inspire Investing LLC's holdings in ADMA Biologics were worth $403,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics during the 3rd quarter worth $30,000. Larson Financial Group LLC purchased a new stake in ADMA Biologics during the 3rd quarter valued at approximately $31,000. GAMMA Investing LLC boosted its holdings in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares during the last quarter. National Bank of Canada FI purchased a new position in ADMA Biologics during the 3rd quarter valued at approximately $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of ADMA Biologics in the third quarter valued at $62,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Down 3.0 %

NASDAQ:ADMA traded down $0.50 during mid-day trading on Friday, reaching $16.08. The company's stock had a trading volume of 1,842,268 shares, compared to its average volume of 2,008,713. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.80 billion, a PE ratio of 57.43 and a beta of 0.76. The stock has a fifty day moving average of $18.56 and a 200-day moving average of $17.46. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the previous year, the firm posted $0.01 earnings per share. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ADMA shares. HC Wainwright upped their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.